Conexeu Sciences (NASDAQ:CNXU) Director Lynn Sebastian Purcell Acquires 202,500 Shares

Conexeu Sciences Inc. (NASDAQ:CNXU) Director Lynn Sebastian Purcell bought 202,500 shares of Conexeu Sciences stock in a transaction that occurred on Thursday, June 18th. The shares were acquired at an average price of $0.80 per share, with a total value of $162,000.00. Following the completion of the acquisition, the director directly owned 2,734,240 shares of the company’s stock, valued at $2,187,392. This represents a 8.00% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Conexeu Sciences Trading Down 13.4%

Conexeu Sciences stock opened at $10.55 on Wednesday. Conexeu Sciences Inc. has a 1 year low of $9.60 and a 1 year high of $18.79.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on CNXU shares. HC Wainwright assumed coverage on Conexeu Sciences in a research note on Monday. They issued a “buy” rating and a $20.00 price target on the stock. Wall Street Zen raised shares of Conexeu Sciences to a “hold” rating in a research note on Saturday, May 30th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $20.00.

Conexeu Sciences Company Profile

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.